STOKE THERAPEUTICS, INC.

Insiders Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
11.48 ^USD	-4.41%		-4.49%	+118.25%

05-07	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating	MT
05-06	Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stoke Therapeutics Appoints Thomas Leggett CFO	04-29	MT
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	04-17	CI
Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors	20/09/23	CI
Insider Sell: Stoke Therapeutics	06/07/23	MT
Insider Sell: Stoke Therapeutics	07/02/23	MT
Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer	12/11/20	CI
Stoke Therapeutics, Inc Announces Appointment of Garry E. Menzel to Both its Board of Directors and Compensation Committee	17/08/20	CI
Stoke Therapeutics, Inc. Appoints Julie Anne Smith to its Board of Directors	04/06/20	CI
Stoke Therapeutics, Inc. Announces Executive Appointments	16/10/19	CI
Stoke Therapeutics, Inc. Appoints Jennifer Burstein to Its Board of Directors	14/06/19	CI
Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer	26/03/19	CI
Stoke Therapeutics, Inc. Announces Management Changes	18/12/18	CI
Stoke Therapeutics Appoints Arthur Tzianabos to Board of Directors	17/09/18	CI
Stoke Therapeutics, Inc. Announces Executive Appointments	17/04/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer